secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001178670-24-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q1 net product rev $365M (+32% YoY); net loss narrows to $0.52/share
----------------------------------------------------------------------------

- Net product revenue $365M, up 32% YoY; TTR franchise $264M (+29%), Rare $101M (+40%).
- GAAP net loss $65.9M ($0.52 per share) vs $174.1M ($1.40) in Q1 2023.
- 2024 guidance reiterated: combined net product revenue $1.4B–$1.5B.
- Zilebesiran: positive KARDIA-2 results; KARDIA-3 initiated, triggering $65M Roche milestone.
- HELIOS-B Phase 3 topline results for vutrisiran on track for late June/early July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/0001178670-24-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/alny-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001178670-24-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer